RxDoctor Payments Data

Kurt Oettel, MD

Hematology & Oncology · la Crosse, WINPI 1770585051

Payments from drug & device makers

What this record shows

3 manufacturers reported payments, led by Pfizer at 58.9% of the total. Reporting peaked in 2021 at $44 and has fallen 66.7% since, to $15 in 2023. That places this record below the midpoint for hematology & oncology clinicians in WI, where the typical reported total is $411.

$75in general payments, 2019–2025

Across 4 payments — averaging $18.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$44
  • Janssen Scientific Affairs, LLC$16
  • Genentech, Inc.$15
$315,361in research payments, 2019–2025

Across 20 payments — averaging $15,768 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$130K
  • Taiho Oncology, Inc.$89K
  • Janssen Research & Development, LLC$52K
  • Ipsen Biopharmaceuticals, Inc$44K

What the payments were for

  • Food & beverage$3141%
  • Education$4459%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$75 in reported general payments places this provider in the 20th percentile of 248 hematology & oncology providers in Wisconsin.

See all hematology & oncology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$66,713
Medicare patients
208
Services billed
1,383

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NubeqaDarolutamide16$200,762
EliquisApixaban37$37,121
Abiraterone Acetate42$5,546
Ondansetron Hcl104$2,034
Tamoxifen Citrate60$1,854
Dexamethasone102$1,202
Prochlorperazine Maleate63$801
Anastrozole56$800
Megestrol Acetate17$688
Potassium Chloride36$646
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen39$480
Prednisone107$441
Gabapentin21$302
Lidocaine Hcl ViscousLidocaine Hcl11$200
Tamsulosin Hcl15$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$44$37,12137 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$16$5,54642 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 248 hematology & oncology providers in Wisconsin.

Other hematology & oncology in la Crosse

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →